SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-24-022065
Filing Date
2024-04-25
Accepted
2024-04-25 16:24:13
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ef20027731_defa14a.htm DEFA14A 22558
2 image001.jpg GRAPHIC 165695
3 image002.jpg GRAPHIC 139815
  Complete submission text file 0001140361-24-022065.txt   444589
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-23186 | Film No.: 24876731
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)